Mycobacterium tuberculosis is a major opportunistic pathogen in patients with HIV/AIDS. Current tuberculosis treatment regimes are severely hampered by the occurrence of multidrug resistant strains of M. tuberculosis (MDR-TB) and there is a critical need for the development of novel chemotherapeutics. We will design and synthesize inhibitors of InhA, the enoyl-reductase enzyme from M. tuberculosis (MTB). InhA, which catalyzes the final step in the fatty acid elongation pathway, is a target for the activated form of isoniazid (INH) a front-line anti-TB drug. Importantly, the large majority of INH-resistant isolates result from mutations in KatG, the enzyme that activates INH, rather than from mutations in the ultimate drug target(s). Consequently, it is hypothesized that inhibitors of InhA, which circumvent the need for KatG activation, will form an effective basis for tackling MDR-TB. The lead compound for inhibitor discovery is triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol), a compound that inhibits InhA with a Ki value of 0.22 mu/M and which has an MIC99 for MTB of 5 mu/g/mL (17 mu/M). The proposed research includes the following specific aims: (1) We will synthesize a library of triclosan analogs using directed synthesis and parallel synthetic methods. (2) We will determine the inhibitory potency of the analogs and analyze the interaction of promising compounds with InhA using techniques such as kinetics, X-ray crystallography and Raman spectroscopy. (3) We will determine MIC99 values against sensitive and resistant TB strains. To evaluate whether InhA is the target for these compounds we will (i) determine MIC99 values in an MTB strain overexpressing InhA and (ii) use promoter-specific reporter fusions coupled with radiolabeled uptake studies and photoaffinity labeling to investigate the mechanism of compound action in live bacteria. The in vivo activity of promising InhA inhibitors will be further analyzed through the NIAID-funded Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF). Information derived from Aims 2-3 will direct the synthesis of additional compounds which will then be submitted for further rounds of screening and evaluation.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Lacourciere, Karen A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
State University New York Stony Brook
Schools of Arts and Sciences
Stony Brook
United States
Zip Code
Neckles, Carla; Eltschkner, Sandra; Cummings, Jason E et al. (2017) Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase. Biochemistry 56:1865-1878
Bommineni, Gopal R; Kapilashrami, Kanishk; Cummings, Jason E et al. (2016) Thiolactomycin-Based Inhibitors of Bacterial ?-Ketoacyl-ACP Synthases with in Vivo Activity. J Med Chem 59:5377-90
Schiebel, Johannes; Chang, Andrew; Shah, Sonam et al. (2014) Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. J Biol Chem 289:15987-6005
Chang, Andrew; Schiebel, Johannes; Yu, Weixuan et al. (2013) Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex. Biochemistry 52:4217-28
Kapilashrami, Kanishk; Bommineni, Gopal R; Machutta, Carl A et al. (2013) Thiolactomycin-based ?-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. J Biol Chem 288:6045-52
Lauinger, Ina L; Vivas, Livia; Perozzo, Remo et al. (2013) Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target. J Nat Prod 76:1064-70
Pan, Pan; Tonge, Peter J (2012) Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr Top Med Chem 12:672-93
Schiebel, Johannes; Chang, Andrew; Lu, Hao et al. (2012) Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20:802-13
Lu, Xuequan; Zhou, Rong; Sharma, Indrajeet et al. (2012) Stable analogues of OSB-AMP: potent inhibitors of MenE, the o-succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. Chembiochem 13:129-36
Liu, Nina; Cummings, Jason E; England, Kathleen et al. (2011) Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. J Antimicrob Chemother 66:564-73

Showing the most recent 10 out of 27 publications